https://www.selleckchem.com/pr....oducts/simnotrelvir.
At 6 weeks US09 treatment resulted in faster wound closure, limited scarring, and suppression of fibrotic markers and immune response. Specifically, fibronectin-extra domain A (EDA), collagen III, and a-smooth muscle actin (p less then 0.05), CD45+ cell infiltration (p less then 0.01), and apoptosis at 24 (p less then 0.01) and 48 h (p less then 0.05) were reduced post-wounding. Corneal thickness and cell proliferation were restored to unwounded parameters. Targeting the DUB, USP10 is a novel strategy to reduce scarring. This study
Like
Comment
Share
